Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

55.77
+0.18000.32%
Volume:442.54K
Turnover:24.70M
Market Cap:10.71B
PE:30.98
High:56.06
Open:55.36
Low:55.21
Close:55.59
52wk High:73.18
52wk Low:50.76
Shares:192.11M
Float Shares:178.10M
Volume Ratio:0.21
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.80
EPS(LYR):1.80
ROE:5.94%
ROA:5.58%
PB:1.76
PE(LYR):30.98

Loading ...

Amicus Therapeutics: Entered License Agreements With Aurobindo & Lupin for Galafold 123 Mg Capsules

THOMSON REUTERS
·
Dec 19, 2025

Amicus Therapeutics: to Grant Aurobindo and Lupin Licenses to Market Generic Versions of Galafold in US From Jan 30, 2037

THOMSON REUTERS
·
Dec 19, 2025

BioMarin Announces New Compensation Package for Incoming Chief Accounting Officer

Reuters
·
Dec 18, 2025

Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?

Simply Wall St.
·
Dec 14, 2025

BioMarin Pharmaceutical Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
Dec 03, 2025

BioMarin Pharmaceutical (BMRN): Assessing Valuation Following Robust Q3 Growth and Upgraded Full-Year Guidance

Simply Wall St.
·
Nov 27, 2025

BioMarin Pharmaceutical Cut to Hold From Buy by Stifel

Dow Jones
·
Nov 06, 2025

BioMarin Pharmaceutical Is Maintained at Outperform by Bernstein

Dow Jones
·
Nov 03, 2025

BioMarin price target lowered to $88 from $95 at Bernstein

TIPRANKS
·
Nov 03, 2025

BioMarin: FDA accepts for Priority Review sBLA for Palynziq

TIPRANKS
·
Oct 29, 2025

FDA Accepts Biomarin's Palynziq® (Pegvaliase-Pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 With Phenylketonuria

THOMSON REUTERS
·
Oct 29, 2025

Biomarin Pharmaceutical Inc - FDA Pdufa Target Action Date Set for Feb. 28, 2026

THOMSON REUTERS
·
Oct 29, 2025

Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth

TIPRANKS
·
Oct 29, 2025

BioMarin Sets $900M-$935M Revenue Target for VOXZOGO by 2025

Deep News
·
Oct 28, 2025

Evercore ISI Remains a Buy on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Oct 28, 2025

Stock Track | BioMarin Pharmaceutical Soars 5.26% Despite Analyst Price Target Cuts; Buy Ratings Maintained

Stock Track
·
Oct 28, 2025

BioMarin price target lowered to $80 from $90 at Truist

TIPRANKS
·
Oct 28, 2025

BioMarin Pharmaceutical Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Oct 28, 2025

BioMarin Pharmaceutical (BMRN) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Oct 28, 2025

BioMarin Pharmaceutical (BMRN) Receives a Buy from Bernstein

TIPRANKS
·
Oct 28, 2025